ClinicalTrials.gg
RecruitingNCT06504056CAPTAINUpdated Nov 18, 2026

Clinical Characteristics and Long-Term Outcomes of Left Ventricular Hypertrabeculation/Noncompaction

An observational study in Left Ventricular Hypertrabeculation and Left Ventricular Noncompaction, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Sex
All
01

Study summary

The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) in patients of all ages. LVHT/LVNC is a heart muscle characteristic identified by cardiac imaging that may occur alone or in association with cardiomyopathies or other heart diseases.

The main questions this study aims to answer are:

  • What are the clinical characteristics and long-term outcomes of patients with LVHT/LVNC in different clinical settings?
  • How do cardiac structure, function, and clinical phenotypes change over time?
  • How are different clinical phenotypes associated with the risk of death, heart failure hospitalization, serious ventricular arrhythmias, and other cardiovascular events?

Researchers will compare patients with isolated LVHT/LVNC, those with associated cardiomyopathies, and those with other cardiac diseases or specific clinical conditions to better understand differences in disease progression and long-term outcomes.

Participants will:

  • Have their existing medical records, cardiac imaging results, and clinical information reviewed.
  • Be followed for up to 5 years through routine medical visits, medical records, or telephone contact, as applicable.
  • Optionally provide biological samples collected during routine clinical care, with appropriate consent.

The study will not change participants' usual medical care or require additional invasive procedures for research purposes.

Read the detailed description

Background and Rationale

Left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) is a cardiac morphological phenotype characterized by prominent ventricular trabeculations and deep intertrabecular recesses. Traditionally considered a distinct cardiomyopathy, LVNC is increasingly recognized as a heterogeneous morphological feature that may occur in isolation or in association with cardiomyopathies, other cardiovascular diseases, and specific physiological or clinical conditions.

The clinical significance of LVHT/LVNC remains uncertain. Although some patients develop heart failure, ventricular arrhythmias, thromboembolic events, or other adverse cardiovascular outcomes, others remain asymptomatic with preserved cardiac function. Differences in imaging diagnostic criteria, underlying cardiac diseases, ventricular function, and myocardial fibrosis may contribute to the substantial heterogeneity observed across patient populations.

Longitudinal evidence regarding the natural history, clinical phenotype transitions, and long-term outcomes of LVHT/LVNC remains limited, particularly in large, multicenter populations encompassing different age groups and clinical backgrounds.

Study Objectives

The CAPTAIN study aims to establish a nationwide multicenter registry to characterize the clinical phenotypes, natural history, and long-term outcomes of patients with LVHT/LVNC.

The specific objectives are to describe the clinical spectrum of LVHT/LVNC; evaluate longitudinal changes in cardiac structure, ventricular function, and clinical phenotypes; assess associations between clinical phenotypes and long-term cardiovascular outcomes; and establish a linked clinical and biological specimen resource for future research.

Study Design and Population

CAPTAIN is a nationwide, multicenter, observational registry cohort study combining retrospective and prospective enrollment.

The retrospective cohort includes eligible patients identified from January 1, 2018, through the date of ethics approval of the amended protocol. Prospective enrollment will continue through December 31, 2045, with core follow-up planned for up to 5 years per participant and final follow-up expected by December 31, 2050.

Patients of all ages with an LVHT/LVNC phenotype confirmed by echocardiography, cardiovascular magnetic resonance (CMR), or other applicable cardiac imaging modalities are eligible.

The study includes patients with isolated LVHT/LVNC, those with associated cardiomyopathies, and those with other cardiac diseases or specific clinical conditions. The presence of concomitant cardiovascular diseases does not automatically exclude participation.

Imaging findings will be evaluated using prespecified criteria and standardized review procedures. Clinical phenotypes will be classified according to underlying cardiac diseases, ventricular structure and function, and relevant clinical characteristics. Overlapping clinical features will be recorded when applicable.

Data Collection and Follow-up

Baseline data will include demographic characteristics, medical and family history, clinical diagnoses, comorbidities, electrocardiographic findings, echocardiographic and CMR measurements, available laboratory and genetic testing results, and treatments received during routine clinical care.

Prospective follow-up is planned at 6 months, 12 months, and annually from years 2 through 5. Follow-up information will be obtained through routine clinical visits, medical records, or telephone contact, as appropriate.

Longitudinal assessments will focus on changes in ventricular structure and function, myocardial trabeculation characteristics, clinical phenotypes, treatments, and cardiovascular outcomes. No additional cardiac imaging examinations are mandated solely for research purposes.

Study Outcomes

The primary outcome is the time to the first occurrence of a composite endpoint comprising all-cause death, hospitalization for new or worsening heart failure, serious ventricular arrhythmias, initiation of long-term mechanical circulatory support, or heart transplantation within 5 years from baseline.

Secondary outcomes include individual components of the primary composite endpoint, cardiovascular death, sudden cardiac death, recurrent heart failure hospitalizations, new-onset atrial fibrillation, ischemic stroke, systemic thromboembolism, and left ventricular thrombus.

Additional assessments include longitudinal changes in ventricular dimensions, ventricular volumes, left ventricular ejection fraction, myocardial fibrosis, trabeculation characteristics, and clinical phenotype transitions.

Biological Specimen Collection and Exploratory Research

An optional nested biospecimen cohort will be established among participants providing appropriate consent.

Research blood and other approved body fluid samples may be collected during clinically indicated sampling procedures. Tissue specimens may be obtained only from residual materials remaining after clinically indicated diagnostic or therapeutic procedures.

The availability of biological specimens is not required for enrollment or continued follow-up.

Linked clinical and biological resources may support future imaging, genetic, pathological, and molecular investigations, subject to applicable consent, ethics approval, and resource governance requirements.

Observational Nature of the Study

CAPTAIN is a non-interventional study. Diagnostic evaluations, medical treatment, device therapy, and surgical procedures will be determined by treating physicians according to routine clinical practice.

No treatment will be assigned by the study, and no additional invasive procedures will be performed solely for research purposes.

02

Conditions studied

  • Left Ventricular Hypertrabeculation
  • Left Ventricular Noncompaction

Keywords

  • Left Ventricular Hypertrabeculation
  • Left Ventricular Noncompaction
  • Clinical Phenotypes
  • Natural History
  • Long-Term Cardiovascular Outcomes
  • Multicenter Registry
03

In context

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) identified at participating medical centers in China. Eligible participants include individuals with isolated LVHT/LVNC, associated cardiomyopathies, other cardiac diseases, or specific clinical conditions. Retrospective participants will be identified from existing clinical records dated January 1, 2018, through the date of ethics approval of the amended protocol. Prospective participants will be consecutively enrolled after approval of the amended protocol through December 31, 2045. Eligibility does not require CMR, genetic testing, or biospecimen availability.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals of any age or sex with left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) confirmed by echocardiography, cardiovascular magnetic resonance (CMR), or other applicable cardiac imaging modalities, according to prespecified imaging criteria and standardized review procedures.
  2. Availability of essential clinical and imaging information sufficient to confirm the LVHT/LVNC phenotype and establish a baseline assessment.
  3. Fulfillment of applicable ethical and requirements, including approved waivers of informed consent for eligible retrospective data or appropriate informed consent for prospective participation. For minors, consent from a parent or legally authorized representative and age-appropriate assent will be obtained as required.

Exclusion criteria

Exclusion Criteria:

  1. Insufficient or unverifiable cardiac imaging evidence to confirm the LVHT/LVNC phenotype after appropriate review.
  2. Insufficient essential clinical information to establish a reliable baseline assessment, with the missing information not recoverable from available medical records.
  3. Explicit refusal to participate or to permit use of clinical information when authorization is required, or other circumstances that preclude participation under applicable ethical or legal requirements.

Additional Eligibility Considerations:

Patients with isolated LVHT/LVNC, associated cardiomyopathies, congenital heart disease, ischemic heart disease, valvular heart disease, or other relevant cardiac or systemic conditions may be included.

CMR, genetic testing, and biospecimen collection are not mandatory for enrollment. The absence of available biospecimens does not constitute an exclusion criterion.

Patients with borderline or uncertain imaging findings will undergo further review and will not be included in the primary study population until the LVHT/LVNC phenotype has been adequately confirmed.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC), identified from existing clinical records between January 1, 2018, and the date of ethics approval of the amended protocol. Retrospectively available demographic, clinical, imaging, laboratory, treatment, and follow-up data will be collected. Patients may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Existing outcomes will be assessed using standardized definitions. No study-assigned interventions or additional clinical procedures will be performed.

  • Prospective Cohort

    Patients of all ages with imaging-confirmed LVHT/LVNC, prospectively enrolled following ethics approval of the amended protocol through December 31, 2045. Participants may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Baseline clinical and imaging information will be recorded, with follow-up planned at 6 months, 12 months, and annually from years 2 through 5. Clinical outcomes and longitudinal changes in cardiac structure and function will be assessed. Optional biospecimens may be collected during routine clinical care with appropriate consent. No study-assigned treatments or additional invasive procedures are required.

06

What researchers measure

Primary outcomes

  1. Time to First Major Adverse Clinical Event (Composite Outcome)

    Time from baseline to the first occurrence of any of the following events: all-cause death; hospitalization for new or worsening heart failure; serious ventricular arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, or appropriate implantable cardioverter-defibrillator therapy); first initiation of long-term mechanical circulatory support; or first heart transplantation. Events occurring before baseline will be recorded as medical history and will not count as incident events. Pre-existing heart failure during the index hospitalization will not count as a new heart failure hospitalization event. The first qualifying event will be used for the composite endpoint.

    Time frame: From baseline through 5 years

Secondary outcomes

  1. Number of Participants with All-Cause Mortality

    Death from any cause during follow-up. The date of death will be determined from available medical records, follow-up contacts, or other permitted sources. Deaths occurring before baseline will not be counted as incident events.

    Time frame: From baseline through 5 years

  2. Number of Participants with Cardiovascular Mortality

    Death attributable to cardiovascular causes, including heart failure, sudden cardiac death, myocardial infarction, stroke, or other cardiovascular conditions. Causes of death will be determined from available clinical documentation and adjudicated using standardized definitions.

    Time frame: From baseline through 5 years

  3. Number of Participants Hospitalized for New or Worsening Heart Failure

    First hospitalization after baseline for new-onset or worsening heart failure requiring inpatient clinical management. Events will be verified using available hospitalization records. Heart failure already present during the index hospitalization will not be counted as a new hospitalization event.

    Time frame: From baseline through 5 years

  4. Number of Participants Experiencing Serious Ventricular Arrhythmias

    First occurrence after baseline of sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, or appropriate implantable cardioverter-defibrillator therapy. Events will be verified using electrocardiographic recordings, device interrogation reports, hospitalization records, or other available clinical documentation.

    Time frame: From baseline through 5 years

  5. Number of Participants Initiating Long-Term Mechanical Circulatory Support

    Number of participants who undergo first implantation or initiation of durable mechanical circulatory support after baseline for advanced heart failure, including durable ventricular assist devices or other long-term mechanical circulatory support systems. Temporary mechanical circulatory support used for acute stabilization will not be counted. Events will be verified using available clinical or surgical records.

    Time frame: From baseline through 5 years

  6. Number of Participants Undergoing Heart Transplantation

    First heart transplantation performed after baseline, as confirmed by transplant records or other available clinical documentation. The transplantation date will be recorded for time-to-event analyses.

    Time frame: From baseline through 5 years

  7. Number of Participants with New-Onset Atrial Fibrillation

    Number of participants without a documented history of atrial fibrillation at baseline who develop new-onset atrial fibrillation during follow-up. Atrial fibrillation must be clinically documented by electrocardiography, ambulatory electrocardiographic monitoring, device interrogation, or other appropriate clinical records. The number and proportion of participants with newly documented atrial fibrillation will be reported.

    Time frame: From baseline through 5 years

  8. Number of Participants with Ischemic Stroke or Systemic Thromboembolism

    Number of participants experiencing at least one clinically confirmed ischemic stroke or systemic arterial thromboembolic event after baseline during follow-up. Events will be identified and verified using available medical records, diagnostic imaging, and relevant clinical documentation. Ischemic stroke and systemic arterial thromboembolism will also be recorded and reported separately.

    Time frame: From baseline through 5 years

  9. Number of Participants with Newly Detected Left Ventricular Thrombus

    Number of participants without documented left ventricular thrombus at baseline who develop newly detected left ventricular thrombus during follow-up. Left ventricular thrombus will be identified by clinically performed echocardiography, cardiovascular magnetic resonance, or other appropriate cardiac imaging. The number and proportion of participants with newly detected left ventricular thrombus will be reported.

    Time frame: From baseline through 5 years

  10. Number of Recurrent Heart Failure Hospitalizations

    Total number of hospitalizations for new or worsening heart failure occurring after baseline, including recurrent hospitalizations in the same participant. Events will be identified from available clinical records and evaluated using appropriate recurrent-event methods.

    Time frame: From baseline through 5 years

  11. Change in Left Ventricular Ejection Fraction

    Change in left ventricular ejection fraction (LVEF), measured in percentage points, from baseline to available follow-up assessments using clinically performed echocardiography or cardiovascular magnetic resonance. Longitudinal changes will be assessed using available repeated measurements, with imaging modalities evaluated separately when appropriate.

    Time frame: Baseline and up to 5 years

  12. Change in Noncompacted-to-Compacted Myocardial Thickness Ratio

    Change in the noncompacted-to-compacted myocardial thickness ratio (NC/C ratio) from baseline to follow-up, assessed using clinically performed echocardiography or cardiovascular magnetic resonance (CMR). The NC/C ratio will be measured using prespecified, modality-specific imaging methods. Changes in the ratio will be evaluated using available repeated imaging measurements. Echocardiographic and CMR measurements will be analyzed separately when appropriate.

    Time frame: Baseline and up to 5 years

  13. Change in Left Ventricular End-Diastolic Dimension

    Change in left ventricular end-diastolic dimension (LVEDD), measured in millimeters, from baseline to available follow-up assessments using clinically performed echocardiography. Longitudinal changes will be evaluated using available repeated measurements, with changes from baseline reported.

    Time frame: Baseline and up to 5 years

Other outcomes

  1. Exploratory Molecular Profiles in Available Biospecimens

    Exploratory characterization of molecular profiles in available, appropriately consented blood, body fluid, and tissue specimens. Analyses may include circulating biomarkers, transcriptomic profiles, protein abundance, metabolite profiles, and other approved molecular measurements. Assay-specific quantitative features will be compared across clinical LVHT/LVNC phenotypes. Biospecimen collection and molecular testing are optional and are not required for enrollment.

    Time frame: Baseline and up to 5 years, when biospecimens are available

  2. Exploratory Associations Between Molecular Signatures and Clinical Phenotypes

    Exploratory assessment of associations between molecular signatures and LVHT/LVNC clinical characteristics, including ventricular function, myocardial fibrosis, trabeculation features, and cardiovascular outcomes. Where suitable tissue specimens are available, analyses may investigate cell-type composition, cell states, molecular pathways, and intercellular signaling. These analyses are exploratory and are not intended to establish causal mechanisms or validate surrogate endpoints.

    Time frame: Baseline and up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Dec 2050, 317 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2024 → Jul 2024, primary completion Sep 2027 → Dec 2050 and completion Sep 2030 → Dec 2050.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
Jul 20, 2024was Oct 2024
Primary completionEst.
Dec 31, 2050was Sep 2027
CompletionEst.
Dec 31, 2050was Sep 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
First Affiliated Hospital of Xi'an Jiantong University is now Recruiting
Nov 18, 2026
Start date
Oct 30, 2024→Jul 20, 2024 (actual)
Nov 18, 2026
Primary completion
Sep 1, 2027→Dec 31, 2050
Nov 18, 2026
Study completion
Sep 1, 2030→Dec 31, 2050
Nov 18, 2026
Enrollment
2000→5000
Nov 18, 2026
Eligibility
Criteria largely rewritten (14 changes)
What changed in the criteria
Inclusion criteria
  • RemovedThe diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • RemovedPatients or their families agreed to participate in the study and authorized informed consent.
  • AddedIndividuals of any age or sex with left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) confirmed by echocardiography, cardiovascular magnetic resonance (CMR), or other applicable cardiac imaging modalities, according to prespecified imaging criteria and standardized review procedures.
  • AddedAvailability of essential clinical and imaging information sufficient to confirm the LVHT/LVNC phenotype and establish a baseline assessment.
  • AddedFulfillment of applicable ethical and informed consent requirements, including approved waivers of informed consent for eligible retrospective data or appropriate informed consent for prospective participation. For minors, consent from a parent or legally authorized representative and age-appropriate assent will be obtained as required.
Exclusion criteria
  • RemovedIncomplete clinical data.
  • RemovedDo not agree to the inclusion or refuse to authorize the informed consent.
  • AddedInsufficient or unverifiable cardiac imaging evidence to confirm the LVHT/LVNC phenotype after appropriate review.
  • AddedInsufficient essential clinical information to establish a reliable baseline assessment, with the missing information not recoverable from available medical records.
  • AddedExplicit refusal to participate or to permit use of clinical information when authorization is required, or other circumstances that preclude participation under applicable ethical or legal requirements.
  • AddedAdditional Eligibility Considerations:
  • AddedPatients with isolated LVHT/LVNC, associated cardiomyopathies, congenital heart disease, ischemic heart disease, valvular heart disease, or other relevant cardiac or systemic conditions may be included.
  • AddedCMR, genetic testing, and biospecimen collection are not mandatory for enrollment. The absence of available biospecimens does not constitute an exclusion criterion.
  • AddedPatients with borderline or uncertain imaging findings will undergo further review and will not be included in the primary study population until the LVHT/LVNC phenotype has been adequately confirmed.
Nov 18, 2026
Interventions
Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Left ventricle group·Right ventricle group·Two sided ventricle group
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in the incidence of mortality rateNow Time to First Major Adverse Clinical Event (Composite Outcome)Time frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year. → From baseline through 5 years
Nov 18, 2026
Secondary outcomes
15 added
What changed in the outcomes
  • AddedNumber of Participants with All-Cause MortalityTime frame: From baseline through 5 years
  • AddedNumber of Participants with Cardiovascular MortalityTime frame: From baseline through 5 years
  • AddedNumber of Participants Hospitalized for New or Worsening Heart FailureTime frame: From baseline through 5 years
  • AddedNumber of Participants Experiencing Serious Ventricular ArrhythmiasTime frame: From baseline through 5 years
  • AddedNumber of Participants Initiating Long-Term Mechanical Circulatory SupportTime frame: From baseline through 5 years
  • AddedNumber of Participants Undergoing Heart TransplantationTime frame: From baseline through 5 years
  • AddedNumber of Participants with New-Onset Atrial FibrillationTime frame: From baseline through 5 years
  • AddedNumber of Participants with Ischemic Stroke or Systemic ThromboembolismTime frame: From baseline through 5 years
  • AddedNumber of Participants with Newly Detected Left Ventricular ThrombusTime frame: From baseline through 5 years
  • AddedNumber of Recurrent Heart Failure HospitalizationsTime frame: From baseline through 5 years
  • AddedChange in Left Ventricular Ejection FractionTime frame: Baseline and up to 5 years
  • AddedChange in Noncompacted-to-Compacted Myocardial Thickness RatioTime frame: Baseline and up to 5 years
  • AddedChange in Left Ventricular End-Diastolic DimensionTime frame: Baseline and up to 5 years
  • Addedother outcomeExploratory Molecular Profiles in Available BiospecimensTime frame: Baseline and up to 5 years, when biospecimens are available
  • Addedother outcomeExploratory Associations Between Molecular Signatures and Clinical PhenotypesTime frame: Baseline and up to 5 years
Nov 18, 2026
Contact
Study contact's phone or email changed: •••3869→•••3865; •••3869→•••3868; l•••@163.com→g•••@xjtu.edu.cn. See the current contact
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • First Affiliated Hospital of Xi'an Jiantong University · Xi'an, ChinaContact added g•••@xjtu.edu.cn · •••3868Contact added y•••@xjtu.edu.cn · •••3865Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 18, 2026
Title
Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN)→Clinical Characteristics and Long-Term Outcomes of Left Ventricular Hypertrabeculation/Noncompaction
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    First Affiliated Hospital of Xi'an Jiantong University is now Recruiting
    Start date Oct 30, 2024→Jul 20, 2024 (now actual)
    Primary completion Sep 1, 2027→Dec 31, 2050
    Study completion Sep 1, 2030→Dec 31, 2050
    Enrollment 2000→5000
    Eligibility Criteria largely rewritten (14 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedThe diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
    • RemovedPatients or their families agreed to participate in the study and authorized informed consent.
    • AddedIndividuals of any age or sex with left ventricular hypertrabeculation/noncompaction (LVHT/LVNC) confirmed by echocardiography, cardiovascular magnetic resonance (CMR), or other applicable cardiac imaging modalities, according to prespecified imaging criteria and standardized review procedures.
    • AddedAvailability of essential clinical and imaging information sufficient to confirm the LVHT/LVNC phenotype and establish a baseline assessment.
    • AddedFulfillment of applicable ethical and informed consent requirements, including approved waivers of informed consent for eligible retrospective data or appropriate informed consent for prospective participation. For minors, consent from a parent or legally authorized representative and age-appropriate assent will be obtained as required.
    Exclusion criteria
    • RemovedIncomplete clinical data.
    • RemovedDo not agree to the inclusion or refuse to authorize the informed consent.
    • AddedInsufficient or unverifiable cardiac imaging evidence to confirm the LVHT/LVNC phenotype after appropriate review.
    • AddedInsufficient essential clinical information to establish a reliable baseline assessment, with the missing information not recoverable from available medical records.
    • AddedExplicit refusal to participate or to permit use of clinical information when authorization is required, or other circumstances that preclude participation under applicable ethical or legal requirements.
    • AddedAdditional Eligibility Considerations:
    • AddedPatients with isolated LVHT/LVNC, associated cardiomyopathies, congenital heart disease, ischemic heart disease, valvular heart disease, or other relevant cardiac or systemic conditions may be included.
    • AddedCMR, genetic testing, and biospecimen collection are not mandatory for enrollment. The absence of available biospecimens does not constitute an exclusion criterion.
    • AddedPatients with borderline or uncertain imaging findings will undergo further review and will not be included in the primary study population until the LVHT/LVNC phenotype has been adequately confirmed.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in the incidence of mortality rateNow Time to First Major Adverse Clinical Event (Composite Outcome)Time frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year. → From baseline through 5 years
    Secondary outcomes 15 added
    What changed in the outcomes
    • AddedNumber of Participants with All-Cause MortalityTime frame: From baseline through 5 years
    • AddedNumber of Participants with Cardiovascular MortalityTime frame: From baseline through 5 years
    • AddedNumber of Participants Hospitalized for New or Worsening Heart FailureTime frame: From baseline through 5 years
    • AddedNumber of Participants Experiencing Serious Ventricular ArrhythmiasTime frame: From baseline through 5 years
    • AddedNumber of Participants Initiating Long-Term Mechanical Circulatory SupportTime frame: From baseline through 5 years
    • AddedNumber of Participants Undergoing Heart TransplantationTime frame: From baseline through 5 years
    • AddedNumber of Participants with New-Onset Atrial FibrillationTime frame: From baseline through 5 years
    • AddedNumber of Participants with Ischemic Stroke or Systemic ThromboembolismTime frame: From baseline through 5 years
    • AddedNumber of Participants with Newly Detected Left Ventricular ThrombusTime frame: From baseline through 5 years
    • AddedNumber of Recurrent Heart Failure HospitalizationsTime frame: From baseline through 5 years
    • AddedChange in Left Ventricular Ejection FractionTime frame: Baseline and up to 5 years
    • AddedChange in Noncompacted-to-Compacted Myocardial Thickness RatioTime frame: Baseline and up to 5 years
    • AddedChange in Left Ventricular End-Diastolic DimensionTime frame: Baseline and up to 5 years
    • Addedother outcomeExploratory Molecular Profiles in Available BiospecimensTime frame: Baseline and up to 5 years, when biospecimens are available
    • Addedother outcomeExploratory Associations Between Molecular Signatures and Clinical PhenotypesTime frame: Baseline and up to 5 years
    Interventions Arms added: Retrospective Cohort·Prospective Cohort; arms removed: Left ventricle group·Right ventricle group·Two sided ventricle group
    Contact Study contact's phone or email changed: •••3869→•••3865; •••3869→•••3868; l•••@163.com→g•••@xjtu.edu.cn. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • First Affiliated Hospital of Xi'an Jiantong University · Xi'an, ChinaContact added g•••@xjtu.edu.cn · •••3868Contact added y•••@xjtu.edu.cn · •••3865Contact added (no phone or email listed)Contact added (no phone or email listed)
    Title Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN)→Clinical Characteristics and Long-Term Outcomes of Left Ventricular Hypertrabeculation/Noncompaction
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06504056
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Jul 20, 2024
Primary completion
Dec 31, 2050 (estimated)
Completion
Dec 31, 2050 (estimated)
Last update
Nov 18, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-2985323865
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion